2024 World Conference on Lung Cancer (WCLC) - Posters-P1.13A.05 Preliminary Results of A Phase II Study of Camrelizumab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for LD-SCLC

P1.13A.05 Preliminary Results of A Phase II Study of Camrelizumab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for LD-SCLC

Back to course

Pdf Summary

This phase II study investigated the combination of camrelizumab with chemotherapy, followed by concurrent chemoradiotherapy, for patients with limited-disease small cell lung cancer (LD-SCLC). Traditional chemoradiotherapy has been used for LD-SCLC, but there is limited data on the efficacy of adding immunotherapy like camrelizumab. The trial, conducted at Shanghai Pulmonary Hospital, enrolled 40 patients. These patients were randomly assigned to receive either camrelizumab in addition to chemoradiotherapy or chemoradiotherapy alone.<br /><br />The study's primary goal was to evaluate the 1-year progression-free survival (PFS) rate. Preliminary results suggest a 1-year PFS rate of 54.5% for the camrelizumab group, compared to 44.4% for the standard treatment group, although the difference is not statistically substantial due to a small sample size. The median PFS time for the camrelizumab group has not yet been reached, indicating potential efficacy, compared to 14.35 months for the control group.<br /><br />Adverse event rates were comparable between groups, with grade 3 or 4 treatment-related adverse events occurring in 58.8% of the camrelizumab group and 52.9% of the chemoradiotherapy-alone group. The most common severe adverse events included hematologic toxicities. Immune-related side effects such as immune pneumonia, thyroid dysfunction, and nephritis were noted but were generally low in incidence.<br /><br />The findings indicate that adding camrelizumab does not significantly increase severe adverse effects, and there is an encouraging indication of improved outcomes, though further investigation with a larger cohort and extended follow-up is necessary to substantiate these preliminary results. Trial registration is documented under ChiCTR2000032275, with Prof. Yaping Xu as the corresponding author.

Asset Subtitle

Yaping Xu

Meta Tag

Speaker Yaping Xu

Topic SCLC & Neuroendocrine Tumors

Keywords

camrelizumab

chemotherapy

chemoradiotherapy

small cell lung cancer

LD-SCLC

progression-free survival

adverse events

immune-related side effects

Shanghai Pulmonary Hospital

clinical trial